Rep. Lisa C. McClain Sells Novartis AG (NYSE:NVS) Shares

Key Points

• Representative Lisa C. McClain sold between $1,001 and $15,000 in shares of Novartis AG on July 22nd, according to a filing.
• Novartis reported a quarterly earnings per share (EPS) of $2.42, surpassing analyst expectations and reflecting a 12.3% year-over-year revenue growth.
• Despite positive earnings, Novartis has a consensus rating of "Hold" and a target price of $123.50 among analysts following recent upgrades and downgrades.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG NYSE: NVS. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novartis stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Novartis Price Performance

Shares of NVS traded up $1.24 during trading hours on Friday, hitting $123.33. 235,252 shares of the stock were exchanged, compared to its average volume of 1,986,524. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. Novartis AG has a 12-month low of $96.06 and a 12-month high of $124.83. The company has a market cap of $260.53 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 1.70 and a beta of 0.62. The stock's 50-day moving average price is $118.54 and its two-hundred day moving average price is $112.82.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%. The business had revenue of $14.05 billion for the quarter, compared to analyst estimates of $13.94 billion. During the same quarter in the prior year, the company posted $1.97 EPS. The company's quarterly revenue was up 12.3% on a year-over-year basis. Research analysts expect that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 price objective on the stock in a report on Friday, August 8th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $123.50.

Institutional Trading of Novartis

A number of hedge funds have recently added to or reduced their stakes in NVS. Brighton Jones LLC lifted its position in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after acquiring an additional 2,666 shares during the period. Russell Investments Group Ltd. lifted its position in Novartis by 6.8% during the 4th quarter. Russell Investments Group Ltd. now owns 10,070 shares of the company's stock worth $980,000 after acquiring an additional 645 shares during the period. Invesco Ltd. lifted its position in Novartis by 18.3% during the 4th quarter. Invesco Ltd. now owns 239,742 shares of the company's stock worth $23,329,000 after acquiring an additional 37,016 shares during the period. Legal & General Group Plc lifted its holdings in shares of Novartis by 8.0% in the 4th quarter. Legal & General Group Plc now owns 4,586 shares of the company's stock valued at $446,000 after buying an additional 339 shares during the period. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Novartis in the fourth quarter valued at approximately $1,541,000. 13.12% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.